LES Foundation | LESI | Print Page | Contact Us | Sign In | Join
Identifying Corridors of Indifference and Sprinting Down Them To In-License Pipeline Products
Tell a Friend About This EventTell a Friend
Identifying Corridors of Indifference and Sprinting Down Them To In-License Pipeline Products

Research Triangle Park (RTP) Chapter Meeting

4/12/2016
When: Tuesday, April 12, 2016
11:45 am - 1:30 pm
Where: Maggiano's Little Italy
The Streets and SouthPoint
8030 Renaissance Parkway, Suite 890
Durham, North Carolina  27713
United States
Contact: Sarah Caley


Online registration is closed.
« Go to Upcoming Event List  

Identifying Corridors of Indifference and Sprinting Down Them To In-License Pipeline Products

Peter Ginsberg will discuss his team’s approach to identifying and evaluating drug candidates of interest and to executing transactions around them. He will also review United Therapeutics’ sale of its priority review voucher to AbbVie for $350 million, as well as characteristics of assets that are attractive to buyers.

Registration Details:
Early by: 3/30/16 

Early                            Regular & Onsite
LES Member: $35        LES Member: $40
Non-Member: $40       Non-Member: $45 

Peter Ginsberg, CFA
Associate Vice President, Business Development, United Therapeutics

Peter Ginsberg, Associate Vice President, Business Development for United Therapeutics Corporation (UT), the largest biotechnology company headquartered in North Carolina. His focus is on acquiring and in-licensing promising drug candidates to expand UT’s pipeline, with an emphasis on orphan oncology and pulmonary indications. Prior to UT, Ginsberg was VP of Business & Technology Development for the North Carolina Biotechnology Center, where his group financed and advised emerging biotechnology companies. He also consulted to a range of biopharma companies on BD transactions and strategic opportunities.

Previously, Ginsberg headed business development and strategic planning for SurModics, a publicly traded leader in the field of drug delivery. He also spent 15 years in the healthcare investment industry and was named a Wall Street Journal All-Star as Piper Jaffray’s lead biotechnology analyst.

Ginsberg acts as a reviewer for the National Cancer Institute and the National Heart, Lung and Blood Institute. He earned an A.B. cum laude in Economics from Princeton University and an M.B.A. from the Tuck School of Business at Dartmouth College, where he was a Tuck Scholar.